Abcl stock forecast.

Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecastsABCL Stock Analysis: Impressive Performance and Optimistic Analyst Forecasts ABCL stock had an impressive performance on September 20, 2023, based on the information provided. The 7 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00.A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...

AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ...Per our algorithmic AbCellera Biologics stock forecast, ABCL’s price could see a decrease of -13.49% over the next five days and reach $ 4.14 on Dec 05, 2023. In the next month, AbCellera Biologics stock is forecasted to lose -1.11% and hit $ …

Hi Fellas, What do you think ABCL at < $6 per share. I already own this share as 60% of the portfolio and my average price is $8. I really like this stock because of the partnership model and the number of bets they have ~ 140 program. I am long term investor and want to hold this until 2028, provided i get somewhere between 5X to 10X return.Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...

The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is 10.10 - 35.70 USD. Based on the ratings of 15, the consensus recommendation for ABCL is BUYFind the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.May 4, 2023 · AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to earnings of $0.54 per share a year ago. The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is 10.10 - 35.70 USD. Based on the ratings of 15, the consensus recommendation for ABCL is BUY

Nov 13, 2023 · High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year.

Of 9 analyst(s) looking at the stock, 0 analyst(s) give ABCL a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. ... Revenue is forecast to shrink -30.00% this quarter before jumping 14.30% for the next one.

Wall Street analysts forecast ABCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABCL is 22.44 USD with a low forecast of 10.1 USD and a high forecast of 35.7 USD .AbCellera Biologics Inc (ABCL). 4.34 -0.26 (-5.65%) USD ... Price to book value is a valuation ratio that is measured by stock price / book value per share.Nov 29, 2023 · See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Inflation hits lowest level since 2021, Fed's preferred gauge shows. Find the latest AbCellera Biologics Inc. (ABCL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight ... ABCL | AI Stock Analysis for AbCellera Biologics Inc ABCL Including Stock Price, Stock Chart, Technical, Fundamental, Sentiment Analysis and More. Start now …Price Performance Review of ABCL. On Monday, AbCellera Biologics Inc [NASDAQ:ABCL] saw its stock jump 2.91% to $4.60. On the same session, the stock had its day’s lowest price of $4.345, but rose to a high of $4.69. Over the last five days, the stock has gained 15.58%. AbCellera Biologics Inc shares have fallen nearly -54.59% since the year ...Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more ...

Abcellera Biologics earnings beat by $0.11, revenue fell short of estimates. By Investing.com. • Aug 03, 2023. Investing.com - Abcellera Biologics (NASDAQ: ABCL) reported second quarter EPS of ...AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00 ...25 sept 2023 ... AbCellera Stock Analysis | Why ABCL Stock is Falling. Nanalyze•4.5K ... | AAPL Stock Analysis | Apple Stock Price Prediction. Parkev Tatevosian ...ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.

Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low.

AbCellera Biologics Stock Forecast. Is AbCellera Biologics Stock Undervalued? The current AbCellera Biologics [ ABCL] share price is $4.47. The Score for ABCL is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. ABCL is currently trading in the 40-50% percentile range relative to its historical Stock ...The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. There was a ~35% reduction in Q2 2021 at ...AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).Get the latest stock price for AbCellera Biologics Inc. (ABCL:US), plus the latest news, recent trades, charting, insider activity, and analyst ratings.AbCellera Biologics Inc. Stock Forecast NASDAQ Stock Exchange > Healthcare > Biotechnology Open Broker Account $4.43 +0 (+0%) At Close: Nov 24, …2 days ago · Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $23.29, which predicts an increase of 436.64%. The lowest target is $12 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy. Dec 1, 2023 · According to 10 stock analysts, the average 12-month stock price forecast for NIO Inc. stock is $12.44, which predicts an increase of 73.99%. The lowest target is $8.00 and the highest is $18. On average, analysts rate NIO Inc. stock as a buy.

When planning outdoor activities or making travel arrangements, having access to accurate weather forecasts is crucial. One commonly used tool is the 7 day weather forecast, which provides an outlook for the upcoming week.

Total Valuation. ABCL has a market cap or net worth of $1.37 billion. The enterprise value is $630.32 million. Market Cap. 1.37B. Enterprise Value. 630.32M.

Nov 29, 2023 · According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price. Nov 25, 2023 · At the close of trading, the stock’s price was $4.50, to imply an increase of 1.58% or $0.07 in intraday trading. The ABCL share’s 52-week high remains $14.15, putting it -214.44% down since that peak but still an impressive 14.0% since price per share fell to its 52-week low of $3.87. Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business.Analyst projections state that ABCL is forecast to be at a low of $10.00 and a high of $34.00. In order for the stock price to hit the forecast high, the stock would need to plunge -660.63% from its current level, while the stock would need to crash -123.71% from its current level to reach the projected low.Find the latest AbCellera (NASDAQ: ABCL) stock information.Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8. A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ...AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F). 7 Wall Street research analysts have issued twelve-month price targets for Mind Medicine (MindMed)'s shares. Their MNMD share price targets range from $7.00 to $75.00. On average, they anticipate the company's share price to reach $25.43 in the next year. This suggests a possible upside of 684.8% from the stock's current price.

We use big data and artificial intelligence to forecast the stock price of AbCellera Biologics Inc Ordinary Shares - ABCL. Our stock price predictions cover a period of 3 months. We cover the US equity market.Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of …The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors?ALK Stock 12 Months Forecast. $51.25. (62.03% Upside) Based on 12 Wall Street analysts offering 12 month price targets for Alaska Air in the last 3 months. The average price target is $51.25 with a high forecast of $70.00 and a low forecast of $41.00. The average price target represents a 62.03% change from the last price of $31.63.Instagram:https://instagram. mortgage advice bureaubroadcome stockoption calculatormetropolitan life stock 1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations. forex and crypto trading appbest mt4 broker for beginners Find the latest SoFi Technologies, Inc. (SOFI) stock quote, history, news and other vital information to help you with your stock trading and investing. tesla unlimited home charging Thinking about investing in AbCellera Biologics because of the upcoming earnings date annual report or stock price forecast? Check out ABCL short interest and earnings date annual report by comparing ABCL insider trading history and institutional ownership breakdown to maximise your investment return on the stock market.Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors.ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts …